Share Price, page-12257

".... but remember Biogen bought Reata for plenty and we are not far away from being in that situation."

My response ... but at what premium?

To me, that is the crux of our current SP woes. As far as I can determine huge premiums are just not paid - if others can provide some examples, please do so. This is Neuren's current dilemma. In order to attract a decent 'fair value' offer (e.g. $50 or more) the SP must rise to a stable, sustainable level far in excess of where we currently sit. Will that occur before the completion of at least one P3? If on the journey ahead the SP recovers to around the ATH ($25), I would give an acceptable T/O offer a chance. If not then we will just have to wait until at least the first P3 result.